CALGB

描述(改编自申请人的摘要)：这是一份 多学科协作研究项目的发展 更有效的预防、检测和治疗人类 各种形式的癌症。这项研究集中了医学界的努力 肿瘤学家、外科医生、放射治疗师、精神病学家、病理学家、基础 科学家、统计学家、流行病学家、护士、药剂师和 临床研究助理在精心设计和进行的研究中询问 相互关联的临床和基础科学问题的答案有助于 对病人护理和减少人群中的癌症有重大意义 面临着更大的发展风险。此项目中包括 (1)新的治疗药物的探索，及其 相关联的毒性，通过一系列的阶段肿瘤疾病 I、II和III研究；(2)疗效和毒性评价 新的养生法包括新旧药物的组合，以努力 更有效地开发协同组合；(3)发展 使用外科手术解决特定肿瘤问题的多模式方法， 最佳组合的免疫、放射治疗措施；(4) 相关基础科学学科的参与，如生物化学， 药理学、细胞生物学和数学在配方和 执行特定的治疗方案；(5)癌症的改善 通过在教育工作中使用这些计划来关心社区 面向博士后和博士后、护士、专职医务人员 和医生；(6)与生物研究相关的评价 临床终点，从而建立更合理的基础癌症 管理；(7)对癌症控制工作的评价，如早期 以及(8)研究癌症的心理社会方面。这 申请成为癌症和白血病B组的永久会员 代表着合作小组临床研究的一个转折点 俄亥俄州立大学在离开其历史悠久的大学时的活动 隶属于西南肿瘤学小组。推动这一变化的是 招募克拉拉·D·布卢姆菲尔德博士、迈克尔·A·卡利古里博士和 阿尔伯特·德拉沙佩勒。这些杰出人物的研究属性 调查人员与俄亥俄州立大学的现有能力协同工作。 将这些不同的优势结合起来将促进创新的发展 临床试验，特别是那些与基础科学相关的试验和 加强俄亥俄州立大学癌症合作小组的参与。

DESCRIPTION (adapted from the applicant's abstract): This is a multi-disciplinary collaborative research project for the development of more effective methods of prevention, detection, and treatment of human cancer in all its forms. This research focuses the efforts of medical oncologists, surgeons, radiotherapists, psychiatrists, pathologists, basic scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research associates on well designed and conducted studies asking interrelated clinical and basic science questions whose answers contribute significantly to patient care and to reduction of cancer within populations at increased risk for its development. Included in this project are the following: (1) the exploration of new therapeutic agents, and their associated toxicities, through a wide range of neoplastic diseases in Phase I, II, and III studies; (2) the evaluation of the efficacy and toxicity of new regimens including combinations of new and old agents in an effort to exploit synergistic combinations more effectively; (3) the development of multi-modal approaches to specific tumor problems using surgical, immunological, and radiotherapeutic measures in optimal combinations; (4) the involvement of pertinent basic science disciplines such as biochemistry, pharmacology, cellular biology, and mathematics in the formulation and execution of specific treatment protocols; (5) the improvement of cancer care in the community by using these programs in the educational effort directed at pre- and postdoctoral students, nurses, allied medical personnel and physicians; (6) the evaluation of biologic studies in correlation with clinical endpoints so as to build toward more rationally, based cancer management; (7) the evaluation of cancer control efforts such as early detection; and (8) the study of the psycho-social aspects of cancer. This application for permanent membership in the Cancer and Leukemia Group B represents a turning point in the cooperative group clinical research activities of The Ohio State University as it leaves its long-standing affiliation with the Southwest Oncology Group. Motivating this change is the recruitment of Drs. Clara D. Bloomfield, Michael A. Caligiuri, and Albert de la Chapelle. The research attributes of these outstanding investigators are synergistic with existing capabilities at Ohio State. Combining these separate strengths will enhance development of innovative clinical trials especially those with basic science correlates and strengthen Ohio State's cancer cooperative group participation.